Clinical Trial Update: Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule [Phase 3]

View source ↗

Summary

This Phase 3 study evaluated the safety and immunogenicity of a two-dose schedule of the 10-valent pneumococcal conjugate vaccine and posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Synflorix (10-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED | Results posted: 2017-04-04